Askel Healthcare Oy

Askel Healthcare to Present First Clinical Trial Results of Its COPLA® Knee Cartilage Implant at the 9th Joint Preservation Congress in Warsaw, Poland on June 14-15, 2024

Fri, Jun 14, 2024 08:00 CET

Askel Healthcare, a Finnish medical technology company pioneering the treatment and repair of focal knee cartilage defects, will present results from its first-in-human Pilot Clinical Trial at the 9th Joint Preservation Congress in Warsaw on June 14-15. The primary endpoint of the trial, safety, was successfully met in all initial ten patients. The trial also provided promising preliminary efficacy data. The COPLA® Cartilage implant is a novel biodegradable solution designed to surgically treat knee cartilage damage. Askel Healthcare aims for this implant to become the global standard

Askel Healthcare has appointed globally renowned orthopedic surgeons and sports medicine specialists to its new Clinical Advisory Board to drive change in the treatment of knee cartilage repair

Wed, May 17, 2023 08:00 CET

Askel Healthcare, a Finnish medical technology company offering a new method for the treatment of knee cartilage defects, has established a Clinical Advisory Board (CAB) representing globally renowned orthopedic surgeons and sports medicine specialists in knee cartilage repair. The newly appointed CAB will have an instrumental advisory role in gathering of high-level clinical evidence of the broad benefits of the COPLA[®] implant and its successful commercialization. COPLA[®] is a biodegradable implant for surgical treatment of cartilage damage in the knee. In the first phase of

Askel Healthcare to raise 5 million euros for clinical research of its COPLA® -implant to treat knee pain caused by cartilage damage

Tue, May 16, 2023 08:00 CET

Askel Healthcare, the Finnish medical technology company offering a new method for the treatment of knee cartilage damage, has started a fundraising campaign to raise up to 5 million euros to finance clinical trials of its COPLA[®] implant. The public phase of the ongoing fundraising campaign started today and closes on 18 June 2023. An investor meeting will take place on 24 May 2023 at 16:00 EEST at VALO Hotel & Work and online. Askel Healthcare’s COPLA[®] implant is a new biodegradable implant for the surgical treatment of cartilage damage in the knee. Askel Healthcare is targeting the

Askel Healthcare has reached an important milestone towards marketing authorization of the COPLA® implant in EU and the USA

Thu, Mar 23, 2023 08:00 CET

Finnish medical technology company Askel Healthcare is developing a new method to treat knee cartilage defects. Askel Healthcare's COPLA® implant is expected to significantly accelerate rehabilitation and enable healing of damaged knee cartilage. From the beginning of January, COPLA® implant is available for selected patients as part of a clinical trial. Three Finnish and one Estonian hospital are participating in the trial. The company is aiming to commercialize the product in the United States and EU by 2028.Knee pain is very common. It is estimated that every fourth 40-year-old person